Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook
2023

Annual Industry Ranking And Forecast

Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing

Most Of The Medtech Top 10 Got Back To Winning Ways On Revenues With Some Unexpected Exceptions

Executive Summary

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

You may also be interested in...



Danaher To Acquire Abcam For About $5.7Bn, Expand Services For Life-Science Industry

After a summer of speculation about who will close the deal with Abcam, tech leader Danaher came out ahead and will acquire Abcam for $24 a share.

Philips Healthcare: Targeting Healthtech Market Recovery Via Value Creation

Quality issues relating to a historical acquisition have held back Philips Healthcare’s financial performance in the post-COVID phase, while market competitors have been able to chart a less bumpy path through the tail end of the pandemic. All are facing supply chain and inflationary pressures.

UPDATED: JPM 2023: Baxter, Medtronic Pursue Simplification As Path To Growth

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel